Correlation of Clinicopathologic Parameters and Immunohistochemical Features of Triple-negative Invasive Lobular Carcinoma

Harbhajanka, Aparna; Lamzabi, Ihab; Singh, Rohit; Ghai, Ritu; Reddy, Vijaya B.; Bitterman, Pincas; Gattuso, Paolo

doi:10.1097/pai.0b013e3182a5a02d

Cited by 10 publications

(11 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we characterized 38 primary TN-ILCs (accounting for 0.1% of all breast cancers diagnosed in our institutions within the study period) in comparison with phenotypically close tumors: TN-IDCs and HR + ILCs, matched by stage and grade. In accordance with the results of others, we found that TN-ILCs were more prevalent in elderly patients than TN-IDCs and HR + ILCs [19], and, appeared more unifocal and more often pleomorphic on microscopic examination, with higher nuclear grades than HR + ILCs [17,19].…”

Section: Discussionsupporting

confidence: 93%

“…In our study, we used a panel of antibodies known as basal markers, including both established (CK5/6 and EGFR) and recently suggested markers (SOX10) [45,46]. We found that only a small subset of TN-ILCs (26.3% versus 93.4% of TN-IDCs) could be classified as BLBCs, which is consistent with previous reports [19]. Our molecular analyses confirmed these results, as most of TN-ILCs were classified as luminal A or HER2-enriched, and not as basal tumors, according to the intrinsic molecular classification.…”

Section: Discussionsupporting

confidence: 89%

“…However, most of these studies included mainly IDC-NSTs and not the triple-negative invasive lobular carcinomas (TN-ILCs), which are rare. Therefore, although some studies have reported the existence of rare TN-ILCs expressing basal cytokeratins [7,15,16], the data for TN-ILC remain scarce [17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations

et al. 2021

View full text Add to dashboard Cite

Primary triple-negative invasive lobular breast carcinomas (TN-ILCs), which do not express hormone receptors and HER2 at diagnosis, are rare and poorly known. In this study, we analyzed the largest TN-ILC series ever reported in the literature, in comparison to phenotypically similar breast tumor subtypes: triple-negative invasive ductal carcinoma (TN-IDC) and hormone receptor-positive invasive lobular carcinoma (HR + ILC). All primary TN-ILCs registered in our database between 2000 and 2018 (n = 38) were compared to tumors from control groups, matched by stage and Elston/Ellis grade, with regard to clinical, pathologic, and immunohistochemical characteristics. A comparative molecular analysis (whole-exome and RNA sequencing using next-generation technology) was also performed. We found that TN-ILC patients were older than those with HR + ILC (P = 0.002) or TN-IDC (P < 0.001). Morphologically, TN-ILCs had aggressive phenotypes, with more pleomorphism (P = 0.003) and higher nuclear grades than HR + ILCs (P = 0.009). Immunohistochemistry showed that TN-ILCs less frequently expressed basal markers (CK5/6, EGFR and SOX10) than TN-IDCs (P < 0.001), while androgen receptor (AR) positivity was more prevalent (P < 0.001). Survival curves analysis did not show differences between TN-ILC and TN-IDC patients, while overall and distant metastasis-free survival were significantly worse compared to those with HR + ILCs (P = 0.047 and P = 0.039, respectively). At a molecular level, we found that TN-ILCs had particular transcriptomic profiles, characterized by increased AR signaling, and associated with frequent alterations in the PI3K network and ERBB2. Interestingly, whole-exome analysis also identified three specific recurrent ESRRA hotspot mutations in these tumors, which have never been described in breast cancer to date and which were absent in the other two tumor subtypes. Our findings highlight that TN-ILC is a unique aggressive breast cancer associated with elderly age, which belong to the luminal androgen receptor subtype as determined by immunohistochemistry and transcriptomic profiling. Moreover, it harbors specific molecular alterations (PI3K, ERBB2 and ESRRA) which may pave the way for new targeted therapeutic strategies.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In whole-body bone scanning, bone metastasis was detected in the T10, T11, L1, L2, L3, and L4 vertebrae. Since the patient was diagnosed with stage IV breast cancer, 6 palliative cycles of 500 mg/m 2 fluorouracil, 50 mg/m 2 doxorubicin, and 500 mg/m 2 cyclophosphamide (FAC) were administered. The patient showed a complete response to the treatment and was followed-up without any medicine for 3 years after the chemotherapy.…”

Section: Case Reportmentioning

confidence: 99%

“…However, although triple-negative lobular carcinomas are rarely encountered in studies related to breast cancer, hormone receptor overexpression is seen at a higher rate. 2 In addition, triple-negative lobular carcinomas is less frequently seen compared with triple-negative carcinomas in invasive ductal carcinoma. 2 In a study, Somali et al found that although invasive lobular histology was less frequent (8.2%), the proportion of medullary, tubular, and mucinous carcinomas was significantly higher (15.9%) in the triple-negative carcinoma group.…”

Section: Introductionmentioning

confidence: 99%

Gastric Metastasis of Triple Negative Invasive Lobular Carcinoma

Geredeli¹,

Doğru

Ömeroğlu

et al. 2015

Rare Tumors

View full text Add to dashboard Cite

Invasive lobular carcinomas are the second most common type (5% to 15%) of invasive breast carcinomas. The most frequent sites of breast cancer metastasis are the local and distant lymph nodes, brain, lung, liver, and bones; metastasis to the gastrointestinal system, especially to the stomach, is rare. When a mass is detected in an unusual place in a patient with invasive lobular carcinoma, it should be kept in mind that such a mass may be either a second primary carcinoma or the metastasis of an invasive lobular carcinoma. In this report, we present a case of gastric metastasis from triple-negative invasive lobular breast cancer. It is important to make an accurate diagnosis by distinguishing gastric metastasis from breast cancer in order to select the best initial treatment for systemic diseases of breast cancer. Considering our case, healthcare professionals should take into account that cases with invasive lobular breast cancer may experience unusual metastases.

show abstract